2017 Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
08/03/17vTv Therapeutics Announces Issuance of U.S. Patent Covering Methods of Treatment Using Azeliragon
HIGH POINT, N.C.--(BUSINESS WIRE)--Aug. 3, 2017-- vTv Therapeutics Inc. (Nasdaq: VTVT) announced today that the U.S. Patent and Trademark Office has issued a patent with claims protecting methods of treatment using azeliragon, the Company’s oral antagonist of the Receptor for Advanced Glycation Endproducts (RAGE) for treatment of mild Alzheimer’s disease. The patent number is 9,717,710 (‘710 Patent). The ‘710 Patent, expiring in October 2034, inc... 
Printer Friendly Version
08/02/17vTv Therapeutics Reports Second Quarter 2017 Financial and Operational Results
HIGH POINT, N.C.--(BUSINESS WIRE)--Aug. 2, 2017-- vTv Therapeutics Inc. (vTv) (Nasdaq: VTVT) today provided a corporate update and reported financial and operational results for the second quarter ended June 30, 2017. “With positive progress in our lead Alzheimer’s and diabetes programs, vTv is pleased to showcase another productive quarter,” said Steve Holcombe, president and CEO of vTv Therapeutics. “At the American Diabetes Association ... 
Printer Friendly Version
07/13/17vTv Therapeutics to Present Two Posters at the 2017 Alzheimer's Association International Conference
HIGH POINT, N.C.--(BUSINESS WIRE)--Jul. 13, 2017-- vTv Therapeutics Inc. (vTv) (Nasdaq: VTVT) today announced that data on the company’s phase 3 Alzheimer’s candidate, azeliragon, an oral antagonist of the Receptor for Advanced Glycation Endproducts (RAGE), will be presented at the 2017 Alzheimer's Association International Conference (AAIC) held in London, England, July 16 – 20, 2017. Details of the poster presentations are listed below: ... 
Printer Friendly Version
06/11/17vTv Therapeutics Presents Data Highlighting Further Potential of TTP273 at American Diabetes Association 77th Scientific Sessions
Lower doses of TTP273 may demonstrate a more pronounced reduction in HbA1c and other key endpoints HIGH POINT, N.C.--(BUSINESS WIRE)--Jun. 11, 2017-- vTv Therapeutics Inc. (vTv) (Nasdaq: VTVT) today announced that results from a Phase 2 clinical study of TTP273, an investigational, oral small molecule GLP-1 receptor (GLP-1R) agonist for the treatment of Type 2 diabetes, were presented at the American Diabetes Association 77th Scientific Sessio... 
Printer Friendly Version
06/08/17vTv Therapeutics to Present Two Posters at the American Diabetes Association’s 77th Scientific Sessions
HIGH POINT, N.C.--(BUSINESS WIRE)--Jun. 8, 2017-- vTv Therapeutics Inc. (vTv) (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease, diabetes and other therapeutic areas, today announced that Company management will present two posters featuring vTv Therapeutics’ orally administered, non-peptide GLP-1R agonist at the American Diabetes Association’s... 
Printer Friendly Version
06/01/17vTv Therapeutics Completes Enrollment of Part B of Pivotal Phase III STEADFAST Trial Evaluating Azeliragon for the Treatment of Patients with Mild Alzheimer’s Disease
-- Azeliragon is the only RAGE receptor antagonist in clinical development for Alzheimer’s Disease -- HIGH POINT, N.C.--(BUSINESS WIRE)--Jun. 1, 2017-- vTv Therapeutics Inc. (vTv) (Nasdaq: VTVT) today announced the completion of enrollment for vTv’s Phase 3 placebo-controlled trial, STEADFAST (Single Trial Evaluating Alzheimer’s Disease Following Addition to Symptomatic Therapy). STEADFAST is evaluating the efficacy and safety of azeliragon, a... 
Printer Friendly Version
05/03/17vTv Therapeutics Reports First Quarter 2017 Financial and Operational Results
HIGH POINT, N.C.--(BUSINESS WIRE)--May 3, 2017-- vTv Therapeutics Inc. (vTv) (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, among other therapeutic areas, today provided a corporate update and reported financial and operational results for the first quarter ended March 31, 2017. “vTv remains committed to advancin... 
Printer Friendly Version
03/10/17vTv Therapeutics to Present at Two Upcoming Annual Investor Conferences
HIGH POINT, N.C.--(BUSINESS WIRE)--Mar. 10, 2017-- vTv Therapeutics Inc. (vTv) (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, among other therapeutic areas, today announced that company management will present a corporate overview at two upcoming investor conferences. Presentation Details: ROTH Capital Pa... 
Printer Friendly Version
02/27/17vTv Therapeutics Reports 2016 Fourth Quarter and Full Year Financial and Operational Results and Recent Highlights
Completed enrollment of Part A pivotal Phase 3 STEADFAST Study of azeliragon in Alzheimer’s Disease Positive Phase 2 results for Type 2 diabetes therapies, TTP273 and TTP399 HIGH POINT, N.C.--(BUSINESS WIRE)--Feb. 27, 2017-- vTv Therapeutics Inc. (vTv) (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, amo... 
Printer Friendly Version